Letter to the Editor: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?

Hu, Yue; Li, Zheng; Li, Zhiping; Zhao, Yaqin; Liu, Qing; Li, Qingfang; Cheng, Xinran.

Afiliação

Hu Y; Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Li Z; Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Li Z; Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zhao Y; Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Liu Q; Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Li Q; Department of Radiation Oncology and Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Cheng X; Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Hepatology ; 2024 Jul 24.

Article em En | MEDLINE | ID: mdl-39042838

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article